トラベア・セラピュティクスの 財務責任者 サンドラ・カルヴィンは 株の一部を売却しました Sandra Calvin, Travere Therapeutics' Chief Accounting Officer, sold a portion of her stock, following other executive sales.

トラベレ・セラピュティクス社の会計責任者 サンドラ・カルヴィンは 最近 会社の株の3,348株を売却し Sandra Calvin, the Chief Accounting Officer of Travere Therapeutics, recently sold 3,348 shares of the company's stock, reducing her ownership by 5%. CEO エリック・M・デュブ氏も同社株の有意な部分を売却した. This comes after several other sales by executives, including CEO Eric M. Dube, who sold a significant portion of his shares. 分析者は前景を前向きに捉え,目標価格を上げている. Analysts have given positive outlooks, with some raising their price targets. 生物製薬会社であるトラヴェレ・セラピュティクスでは 珍しい病気を中心に 機関投資家が 持株を増やしています Travere Therapeutics, a biopharmaceutical company focused on rare diseases, has seen institutional investors also increasing their holdings.